This trial is evaluating whether Receives SCOUT at biopsy will improve 1 primary outcome in patients with Breast Cancer. Measurement will happen over the course of up to 1 year.
This trial requires 500 total participants across 2 different treatment groups
This trial involves 2 different treatments. Receives SCOUT At Biopsy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
While there is evidence that some environmental factors increase breast cancer risk, the evidence is not strong enough to justify any changes in advice for prevention. The causal relationship between some non-occupational factors and breast cancer risk is stronger in women with a strong familial history of breast cancer.\n
Breast cancer is the most common cancer diagnosed among women in the US, and it accounts for nearly 13% of cancer deaths. The incidence rates were higher among black and Hispanic women than among white women. The number of new patients diagnosed with breast cancer in the USA for 2014 was approximately 100,400. The estimated number of women who suffer from breast cancer each year was 174,600.
In a recent study, findings indicated that many symptoms and signs associated with [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) may not be seen at first diagnosis of breast cancer. A patient may not complain about breast pain or discomfort if they are worried about how the pain will affect their social life. The pain and discomfort might only occur as a symptom of advanced breast cancer.
The incidence of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) has increased in Canada, and a female is more likely to get breast cancer during her lifetime than a male. The risk of breast cancer increases with age; the five-year risk is 11% for a woman over 50. The risk is higher in some parts of the country than in others. There is no specific factor that enhances or decreases the risk. Breast cancer is the second leading cause of cancer death in Canada, after lung cancer. The five-year survival rate is 77% in all stages, and is related to the stage of cancer at the time of diagnosis.
A treatment option for [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) consists of local adjuvant surgical procedures (such as lumpectomy) and systemic hormonal therapy (and sometimes chemotherapy). Radiation therapy may also be necessary in certain cases. The most common alternatives to standard breast-conserving surgeries are mastectomy or lumpectomy.\nquestion: What are common treatments for cancer treatment-related bone pain?\answer: Surgical removal of the tumor in some cases may improve the bone pain, and patients have also been able to improve with more conservative treatments such as chemotherapy alone, radiation therapy alone, or radiation therapy with pain management options.
Cured is a term which is often used in discussions of treatment in the clinical cancer environment, but has little scientific value. Thus, it is imperative that we abandon the term and begin to use the standard terminology of cure and remission in regard to breast cancer, and the concept of cure should be introduced into the language of cancer.
A combination of local-regional-chemotherapy followed by breast radiotherapy has a significant improvement versus a placebo in disease-free survival in patients with locally advanced and in operable breast cancer. Recent findings confirms that the use of a standardized regimen of chemotherapy can significantly improve the survival in patients with locally advanced breast cancer.
Patient age, axillary lymph node involvement, and breast surgery type are independent predictors of the incidence of scotoma. However, patients aged younger than 60 and with unilateral nonpalpable breast disease are at a higher risk of developing scotoma. In an effort to reduce costs, scotoma can be observed with patient satisfaction.
The average age at diagnosis of breast cancer in the United States is 65 in both sexes. Although the age distribution is approximately normal, there is a gradual increase in the number of women diagnosed with the disease from age 40–45 to 65+. The increase in diagnosis from age 40–45 to 44–45 years corresponds with the age at onset of breast cancer in women without a history of the disease. Increasing the screening rates may be needed for women in this age category.
I can't remember when I had my first biopsy. It was at least 20 years ago that I have had my first lymph node biopsy—a procedure performed to examine the lymph nodes for cancer. A pathologist would usually biopsy every node that shows cancer activity. But since I have had my many biopsies and my lymph node biopsy was done more than 20 years ago, my surgeon should have biopsied the first node in the left armpit when I had breast cancer. Otherwise, I would have been subjected to a less accurate and less effective therapy than I was.
All in all, when you know your biopsy has been sent, it has proven there is no problem. But until the histology of the original biopsy is reported to the pathologist, you cannot know for sure. There is a great need for a standardized algorithm to provide a level of confidence in reporting such cases.
It appears that the current practice of administering a single radiologic exam before a [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) fine needle biopsy allows for a significant increase in the frequency of cancer. This finding has important implications as many patients who have presented with suspicious findings on mammography require a tissue sample for diagnostic confirmation. A single radiologic exam may in some cases obviate the need for a biopsy as the lesion appears sufficiently suspicious to justify performing an excision. This observation also supports the growing body of evidence suggesting that the cumulative frequency of cancer is lower following excisional biopsy as compared to stereotactic core percutaneous biopsy.